- Home
- OPK vs COLL Comparison
OPK vs COLL Comparison
Compare OPK & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OPK | COLL |
|---|---|---|
| Founded | 2007 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.5B |
| IPO Year | 1995 | 2015 |
Fundamental Metrics
Financial Performance| Metric | OPK | COLL |
|---|---|---|
| Price | $1.28 | $49.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $2.28 | ★ $47.50 |
| AVG Volume (30 Days) | ★ 3.2M | 488.1K |
| Earning Date | 10-29-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.63 |
| Revenue | $642,067,000.00 | ★ $757,067,000.00 |
| Revenue This Year | N/A | $26.35 |
| Revenue Next Year | N/A | $3.67 |
| P/E Ratio | ★ N/A | $30.66 |
| Revenue Growth | N/A | ★ 26.34 |
| 52 Week Low | $1.11 | $23.23 |
| 52 Week High | $2.04 | $50.01 |
Technical Indicators
Market Signals| Indicator | OPK | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 39.58 | 69.54 |
| Support Level | $1.27 | $48.50 |
| Resistance Level | $1.37 | $49.92 |
| Average True Range (ATR) | 0.05 | 1.25 |
| MACD | -0.00 | -0.21 |
| Stochastic Oscillator | 10.13 | 76.67 |
Price Performance
Historical ComparisonAbout OPK OPKO Health Inc.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.